Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of nab-paclitaxel combined with carboplatin for Chinese
patients with triple-negative and HER2-positive breast cancer in the neoadjuvant setting.